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Abstract
Tankyrase (TNKS) 1/2 are positive regulators of WNT signaling by controlling the activity of
the ß-catenin destruction complex. TNKS inhibitors provide an opportunity to suppress
hyperactive WNT signaling in tumors, however, they have shown limited anti-proliferative
activity as a monotherapy in human cancer cell lines. Here we perform a kinome-focused
CRISPR screen to identify potential effective drug combinations with TNKS inhibition. We
show that the loss of CDK4, but not CDK6, synergizes with TNKS1/2 blockade to drive G1
cell cycle arrest and senescence. Through precise modelling of cancer-associated muta-
tions using cytidine base editors, we show that this therapeutic approach is absolutely
dependent on suppression of canonical WNT signaling by TNKS inhibitors and is effective in
cells from multiple epithelial cancer types. Together, our results suggest that combined
WNT and CDK4 inhibition might provide a potential therapeutic strategy for difficult-to-treat
epithelial tumors.
Introduction
Almost all colorectal cancers (CRCs) carry activating mutations in the WNT pathway, most
often due to loss-of-function truncations in the adenomatous polyposis coli (APC) tumor sup-
pressor[1, 2]. Numerous studies have shown that hyperactivation of the WNT pathway is an
oncogenic driver in the intestine[3–5], and in many cases, suppression of WNT signaling is
sufficient to induce cell differentiation[6] and tumor regression in animal models[7–12]. We
recently showed that restoring endogenous regulation of the WNT pathway by re-expressing
normal levels of APC, is sufficient to induce disease regression in established colorectal can-
cers[8, 9].
Efforts to target WNT signaling pharmacologically have explored multiple nodes of inhibi-
tion, including blocking WNT ligand secretion and direct targeting the downstream
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transcriptional effector, ß-catenin[13, 14]. We reasoned that modulating WNT signaling
through the same mechanism by which APC acts would provide the best opportunity for well-
controlled WNT regulation. While it is not feasible to genetically restore APC in human
CRCs, it is possible to reinforce the activity of the APC/AXIN/ß-catenin destruction complex
by increasing the levels of the scaffold proteins AXIN1/2. Tankyrase enzymes (TNKS and
TNKS2) are functionally-redundant members of the poly-ADP ribose polymerase (PARP)
family that mediate the PARsylation and degradation of AXIN1/2, and thus, TNKS inhibition
stabilizes AXIN and reinforces endogenous suppression of WNT signaling. Numerous small
molecules have been described that enable selective TNKS1/2 blockade and WNT pathway
suppression in CRC cell lines [15–18].
Despite their ability to dampen hyperactive WNT and suppress tumor growth in model sys-
tems, TNKS inhibitors do not always show anti-proliferative effects as single agents in human
CRC cell lines[17, 19, 20]. However, when mitogenic signaling is limited by the reduction of
serum in the culture media, TNKS inhibition can block growth and proliferation of otherwise
resistant cells[16, 21]. This suggests that inhibition of parallel mitogenic signals may synergize
with TNKS inhibitors to control tumor cell growth. Indeed, blocking MEK, PI3K, or EGFR
can enhance the anti-tumor effect of TNKS inhibitors[17, 19, 20]. Here we perform a domain-
focused kinome CRISPR library screen[22], aiming to identify the most critical mitogenic sig-
naling components that mediate resistance to TNKS inhibition, with the goal of defining com-
bination approaches to enhance tumor cell response. We identify CDK4 as a synthetic
vulnerability in colorectal cancer cells and show that dual inhibition of TNKS and CDK4
drives a potent cell cycle arrest in a range of human epithelial cancer cell lines including colon,
breast and lung cancer cells. Recently, Lord and colleagues identified a novel TNKS1/2 inhibi-
tor (MSC2504877) and identified several synergistic targets through siRNA and drug-based
screens, including CDK4/6[23]. We demonstrate that this drug synergy is absolutely depen-
dent on suppression of canonical WNT signaling, and that the TNKS and CDK4 combined
inhibition promotes enhanced cellular senescence. Our findings support recent work with an
independent TNKS inhibitor and highlight the potential for WNT-targeted therapies to sensi-
tize CRCs to FDA-approved CDK4/6 inhibitors.
Results
A kinome-focused screen identifies vulnerabilities in colorectal cancer
Tankyrase inhibition suppresses WNT signaling in diverse human and mouse cell types by sta-
bilizing AXIN1 protein, resulting in decreased stability of beta-catenin and subsequently
reduced transcription of TCF target genes[16, 17, 19–21, 24–26] (Fig 1A), yet TNKS inhibition
alone is not sufficient to decrease cell proliferation in these cells under normal growth condi-
tions[16, 20] (S1A Fig). However, in low serum conditions (2% FBS), cells become sensitive to
TNKS inhibition[21] (Fig 1B). Similarly, suppression of MAP kinase activity via MEK inhibi-
tion synergizes with TNKS blockade[17] (Fig 1C). To identify other potential signaling depen-
dencies that drive TNKS inhibitor resistance, we set out to evaluate the requirement for all
human kinases, using a focused CRISPR-based loss-of-function screen.
We first identified a minimal dose of the TNKS inhibitor, XAV939[21] (hereafter XAV)
that induced maximal AXIN1 stabilization (Fig 1D) and confirmed that treatment with this
dose (1uM) maintained elevated AXIN1 levels up to 48hrs (S1B Fig). We then generated stable
Cas9-expressing clones of the CRC line DLD1 (see Methods) and confirmed that each line
(hereafter, LC9) could induce rapid depletion of sgRNAs targeting essential genes (e.g. CDK1
or RPA3)[22]; We chose the three most efficient clones as replicates for the screen (S2A Fig).
Tankyrase inhibition sensitizes cells to CDK4 blockade
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Fig 1. A kinome-focused screen to identify novel vulnerabilities in colorectal cancer. a. Relative mRNA levels measured by
quantitative RT-PCR (qRT-PCR) in DLD1 cells treated with DMSO or XAV for 24h as indicated. b. Colony-forming assays in
DLD1 cells grown in the indicated FBS and XAV concentrations (left); quantification of the experiment shown in (b) (n = 3
independent experiments, represented is mean and SEM). P values are shown (two-tailed Student’s t test). c. Colony-forming
assays in DLD1 cells grown in 10% FBS and the indicated Trametinib concentrations (left). Quantification of the experiment
shown (right panel) (n = 4 independent experiments, represented is mean and SEM). P values are shown (two-tailed Student’s t
test). d. Western blot showing Axin1 stabilization upon DLD1 treatment (24h) with the indicated XAV concentrations. e.
Schematic depiction of the backbone (LRG) in which the gRNA human kinome library was cloned (top). Outline of the human
kinome gRNA library screen for XAV dependencies (bottom). f. Dot-plot representation of the log10 gRNA counts of DMSO-
treated DLD1 cells at 14 population doublings (D17) vs sorted GFP-positive DLD1 cells at Day 3 post-gRNA library transduction
(D3). Indicated are positive (green) and negative (blue) controls for gRNA depletion. Novel vulnerabilities are depicted in red
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PLOS ONE | https://doi.org/10.1371/journal.pone.0226645 December 31, 2019 3 / 20
As expected, prolonged treatment of the clonal lines with 1uM XAV caused only a minor sup-
pression in cell proliferation over three weeks in culture (containing 10% serum) (S2B Fig).
We next introduced a domain-focused kinome library targeting 482 human kinases (~6
sgRNAs/gene)[22] into each LC9 line with an average representation of 2000x (Fig 1E). Analy-
sis of gRNA abundance in flow-sorted (GFP-positive) populations showed a high concordance
between replicates with more than 99% of expected sgRNAs represented in each of the pools
and good correlation across biological replicates (S1 Table; S2C Fig). Following expansion for
7 days to deplete sgRNAs targeting essential genes, each population was treated with either
DMSO or 1uM XAV for 14 population doublings and relative abundance of individual
sgRNAs was compared to post-sort (pre-treatment) samples (Fig 1E). As expected, control,
neutral sgRNAs showed no significant change in abundance (Fig 1F and S2D and S3 Figs),
while those targeting essential genes (e.g. CDK1, AURKB, CDK7) were strongly depleted in
both DMSO and XAV conditions (S2 and S3 Tables, Figs 1F and 1G and 2). We also identified
a subset of sgRNAs (VRK1, CSNK1A1, PIK3R4, SMG1, and BUB1) that were strongly depleted
in DLD1 cells but not universally depleted in an array of cell lines assayed using an identical
gRNA library[22] (Fig 2A). We confirmed some of these genes, including VRK1, CSNK1A1
and PIK3R4, were also essential in a range of other human CRC lines, suggesting that they may
represent cell or tumor-type specific vulnerabilities (Fig 2B).
Synthetic lethal interaction of Tankyrase inhibition with EGFR or CDK4/6
inhibition
We identified two genes that showed significant depletion (fold-change (FC) > 2, adjusted p-
value < 0.05) of two or more sgRNAs in XAV-treated cells, compared to DMSO treatment
(S3A Fig). These were epidermal growth factor receptor (EGFR), and cyclin-dependent kinase
4 (CDK4) (S4 Table and Fig 1G). Similar to MEK inhibitors, EGFR-targeting agents have been
previously been linked to TNKSi resistance[19, 27] and we confirmed this synergy with multi-
ple sgRNAs targeting EGFR, and the small molecule EGFR inhibitor, Gefitinib (Fig 3A–3C).
We decided to focus on CDK4 because it had not been directly linked to TNKS or WNT path-
way hyperactivation. Further, there are multiple clinically effective inhibitors targeting CDK4/
6 (Palbociclib, Ribociclib, and Abemaciclib), though none are yet approved for CRC[28].
To assess how specific this synergy was for CDK4, we compared gRNA depletion across the
entire CDK family in DMSO vs XAV-treated cells (Fig 4A). While some CDK genes are
known essential fitness genes (i.e. CDK1, CDK7 or CDK9), other members had an intermedi-
ate impact (CDK2 and CDK4), and some were completely dispensable for DLD1 cell prolifera-
tion (CDK5, CDK6, and CDK10) (S3A Fig). Importantly, only CDK4 (and not the other
closely related partner of Cyclin D, CDK6), showed enhanced depletion in the presence of
XAV (S3A Fig). We validated the synergy between loss of CDK4 and TNKS inhibition using
four independent CDK4 gRNAs targeting CDK4, all of which reduced cell fitness in fluores-
cence-based competitive assays (Fig 4B and 4C). Consistent with the results from the screen,
depletion of CDK6 using two effective gRNAs only caused a minor disadvantage in competi-
tion assays, which was not significantly different between DMSO or XAV-treated cells (S3A
Fig and Fig 4A–4C). These results highlight a specific CDK4 dependence upon TNKS inhibi-
tion in colorectal cancer cells.
(CSNK1A1, VRK1, PIK3R4). g. Normalized gRNA counts at Sorting (gray), DMSO-PDL14 (blue) and XAV-PDL14 (red) in DLD1
cells. Results are shown normalized to sorting, n = 3 independent clones, as mean and SEM. Adjusted p values were calculated
using DESeq. See S1 Table.
https://doi.org/10.1371/journal.pone.0226645.g001
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Fig 2. New vulnerabilities in colorectal cancer. a. Heatmap showing comparison of the gRNA depletion for potential
lethal targets found in DLD1 (this study, arrowhead) vs the panel of cell lines described in Tarumoto et al, 2018. The
colorectal-specific candidates are labelled. b. Validation of candidate colorectal-specific vulnerabilities in a panel of
colorectal cancer cell lines from ATCC, through fluorescence-based competition assays. EV (empty gRNA control
vector) and RPA are included as positive and negative controls, for reference of size effect (n = 3 independent clones
for each cell line).
https://doi.org/10.1371/journal.pone.0226645.g002
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To confirm the synthetic lethality observed upon inhibition of TNKS together with gRNA-
mediated CDK4 depletion was not specific to CRISPR-mediated CDK4 disruption, we treated
DLD1 cells with varying concentrations of XAV and the CDK4/6 inhibitor Palbociclib. As
expected, we observed increased suppression in colony formation following treatment with
both drugs, that was greater than the additive effects of each treatment alone (Fig 4D and 4E).
Conversely, to confirm the synergy observed was due to direct TNKS suppression and not
inhibition of other PARP family members, we used two independent doxycycline(dox)-regu-
lated shRNAs against TNKS1/2. As expected, shRNA-mediated depletion of TNKS sensitized
DLD1 cells against Trametinib, Gefitinib and Palbociclib in the presence of dox (Fig 4F and
4G, S3B and S3C Fig). Finally, we further confirmed the on-target effect of TNKS inhibition in
sensitizing cells to CDK4 blockade by treating cells with commercially-available small mole-
cules that block TNKS activity via distinct mechanisms. TNKS inhibition through either the
nicotinamide subsite (XAV939), adenosine subsite (G007-LK) or via a dual adenosine and nic-
otinamide binder (NVP-656), synergized with Palbociclib to suppress cell proliferation (Fig
4H).
The synergy between TNKS and CDK4 inhibition was not restricted to DLD1 cells, as we
observed similar effects of TNKS silencing and Trametinib or Palbociclib treatment in the
colorectal carcinoma cell line SW480 (bearing an APC truncating mutation, similar to DLD1)
Fig 3. Synergistic EGFR and TNKS inhibition. a. Fluorescence-based competitive assay demonstrating enhanced
inhibition of cell growth upon simultaneous TNKS inhibition and EGFR knock-out using four independent gRNAS. b.
Western blot detection of EGFR in DLD1 cells treated with the indicated gRNAs. c. Cell growth inhibition in DLD1
cells treated with the indicated inhibitors for 15 days.
https://doi.org/10.1371/journal.pone.0226645.g003
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Fig 4. Simultaneous inhibition of TNKS and CDK4 is synthetic lethal. a. Normalized gRNA counts of Cyclin-
dependent kinase (CDK) family members (DMSO D17 values, normalized to Sorting D3). b. Fluorescence-based gRNA
competition assays by flow cytometry. Shown in mean and SEM, n = 3 independent DLD1 clones. P values were
calculated using two-tailed Student’s t test. EV = control empty gRNA vector. c. Western blot in DLD1-LC9 cells stably
transduced with CDK4 or CDK6 gRNAS and selected in Puromycin and Blasticydin for 5 days. d. Colony forming assays
of DLD1 cells grown in 10% FBS in the indicated inhibitor concentrations. e. Growth inhibition scores, shown as % of
growth inhibition (normalized to non-treated conditions), of DLD1 cells in the indicated inhibitor concentrations. f.
Western blot showing TNKS silencing with single or tandem shRNA constructs in DLD1 cells. Tandem TNKS silencing
induces AXIN1 protein to a similar level as treatment with XAV939. g. Colony forming assays of DLD1 cells stably
transduced with the indicated dox-inducible TNKS1/2 or Renilla shRNAs, respectively, and grown in colony-forming
conditions in the presence of the indicated inhibitors +/- dox. TNKS1/2 shRNAs efficiency by western blot (bottom). g.
Relative growth of DLD1 cells grown in colony-forming conditions in the presence of the indicated inhibitors +/-
Palbociclib. N = 3 independent experiments, mean and SEM are shown (Student’s t test).
https://doi.org/10.1371/journal.pone.0226645.g004
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(S3C Fig). Further, we saw enhanced growth suppression in multiple breast and lung cancer
cell lines treated with XAV and Palbociclib, demonstrating a consistent combinatorial effect of
TNKS and CDK4 blockade across a broad spectrum of cancer cell lines of epithelial origins
(S3D Fig).
Synergy of combined TNKS and CDK4/6 inhibition is dependent on WNT
pathway suppression
TNKS has a number of PARsylation targets other than AXIN1/2, including telomere binding
factor TRF1[29], the mitotic regulator NUMA1[30], and YAP/TAZ-associated angiomotin
(AMOT) proteins[27], among others. To determine whether TNKS/CDK4 inhibitor synergy
was dependent on suppression of WNT signaling we used CRISPR base editing to engineer an
S45F missense mutation in endogenous CTNNB1[31] in DLD1 cells, rendering it insensitive
to regulation by the APC destruction complex. We derived CTNNB1S45F DLD1 clones and
treated them with XAV (1uM) and increasing doses of Palbociclib (10-1000nM). While XAV-
treated parental cells were 3-fold more sensitive to Palbociclib (IC50 250 for XAV-treated cells
and 800nM for DMSO-treated cells, respectively), CTNNB1S45F isogenic cells showed no
change in response to treatment with XAV (Fig 5A–5D). Similarly, XAV-treatment of a natu-
ral CTNNB1S45F mutant cell line, HCT116, showed no increased sensitivity to Palbociclib, or
genetic disruption of CDK4 by CRISPR (S4 Fig). These results suggest that TNKS-mediated
sensitization to CDK4 inhibition is absolutely dependent on the ability of TNKS inhibitors to
suppress WNT signaling. Importantly, we saw identical effects when XAV was combined with
Trametinib or Gefitinib, implying that most reported drug synergies with TNKS inhibitors are
likely mediated through WNT suppression (S4 Fig).
Tankyrase inhibition enhances the cytostatic effects of Palbociclib
Palbociclib exerts its effects on target cells by blocking the activity of the D-type cyclin-depen-
dent kinases CDK4/6 and subsequently inducing a G1 cell cycle arrest[32]. To understand
how the combination of CDK4/6 and TNKS inhibition could lead to reduced cell growth in
epithelial cells, we analyzed cell cycle kinetics in XAV and Palbociclib treated DLD1 cells. As
expected, Palbociclib treatment caused a reduction in the proportion of cells in S-phase and a
corresponding increase in the in the percentage of cells in G0/G1 (Fig 6A and 6B). Combined
treatment with XAV caused a further drop in S-phase cells, resulting in more than 70% of cells
arrested in G0/G1.
During analysis of the individual and combination treatments, we noted that XAV/Palboci-
clib treated cells showed a flattened morphology and increased intracellular vacuoles, charac-
teristic of cellular senescence. Indeed, while XAV or Palbociclib only treated cells showed low
senescence-associated beta-galactosidase (SA-ßGal) activity (5% and 17%, respectively; Fig
6C), combined XAV/Palbociclib treatment induced a 2.5-fold increase in SA-ßGal. Increased
senescence was also observed in a panel of colorectal, breast and lung cancer cell lines upon
combined therapy using XAV and Palbociclib (Fig 6D and 6E). Together, this data suggests
that, combined inhibition of TNKS and CDK4 leads to enhanced cell cycle arrest and cellular
senescence. It is not yet clear whether senescence-associated transcriptional changes and
senescence-associated secretory phenotype (SASP) is consistently activated across different
cell lines, or in vivo tumors.
Discussion
Activation of the WNT pathway is a driver in many cancer types, particularly colorectal can-
cer. However, suppression of hyperactive WNT is not sufficient to induce cell cycle arrest in
Tankyrase inhibition sensitizes cells to CDK4 blockade
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many human cancer cell lines. Using a domain-focused human kinome CRISPR screen, we
sought to identify signaling dependencies that could enhance the sensitivity of CRC cells to
WNT suppression by TNKS1/2 inhibition.
Previous in vitro and in vivo studies have shown that inhibition of either MEK1/2, EGFR,
or AKT can enhance the effect of TNKS blockade[17, 19, 20]. To our surprise, we identified
only two genes whose depletion synergized with TNKS inhibition: EGFR and CDK4. Though
we did identify EGFR as a synthetic interaction with TNKS in DLD1 cells, neither MEK nor
Fig 5. CDK4 and TNKS synergy is dependent on canonical WNT signaling. a. Schematic representation of
competition assays, using a LRT2B backbone to track CTNNB1-S45F modified cells. b. Fluorescent competition assay
showing the percentage of TdTomato-positive cells after 14 PDLs in the indicated drug concentrations. N = 4
independent experiments, p values were calculated using Student’s t test. c. Colony-forming assays of parental (top
panels) or S45F-edited (bottom panels) DLD1 cells, treated with the indicated drug concentrations. d. Relative cell
growth, represented as % of DMSO-treated DLD1 cells, calculated from colony-forming assays cells of parental (top)
or CTNNB1-S45F (bottom) backgrounds. Cells were treated with increasing Palbociclib concentrations in the absence
(black lines) or presence of XAV. N = 3 independent assays, represented is mean and SD.
https://doi.org/10.1371/journal.pone.0226645.g005
Tankyrase inhibition sensitizes cells to CDK4 blockade
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Fig 6. TNKS inhibition reinforces CDK4 inhibition-mediated senescence. a. Flow cytometry analysis of EdU incorporation (left) and EdU/PI G0/G1
arrest (right panel) in DLD1 cells treated for 15 days with the indicated inhibitors. Represented is mean and SEM, p values indicate two-way Student’s t
test (n = 3 independent experiments). b. Senescence-associated beta-galactosidase (SABG) staining in DLD1 cells, treated for 15 days, as indicated.
Arrows indicate positive-scored cells. Scale bar, 25 microns. c. Quantification of the percentage of SABG-positive cells from the experiment shown in (b).
N = 3 independent experiments, SEM and mean are depicted. P values correspond to two-sided Student’s t test. d. Flow cytometry analysis of EdU
incorporation in colon, breast and lung cell lines treated for 15 days with the indicated inhibitors. Represented is mean and SEM, p values indicate two-
way Student’s t test (n = 3 independent experiments). e. Quantification of the percentage of SABG-positive cells in colon, breast and lung cells. N = 3
independent experiments, SEM and mean are depicted. P values correspond to two-sided Student’s t test (top panels). Representative images of the
results shown in (d). Scale bars, 25 microns (bottom panels).
https://doi.org/10.1371/journal.pone.0226645.g006
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AKT scored. As DLD1 cells are sensitive to combined treatment with TNKS and MEK inhibi-
tors (Fig 1C)[17], we expect that the failure to identify MEK or AKT is due to the functional
redundancy of multiple MEK and AKT family members. This observation highlights the limi-
tation of single sgRNA libraries for studying functionally redundant gene families, but also
implies there may be other unidentified kinase targets that synergize with TNKS blockade.
Interestingly, our second hit (CDK4) is known to have a functionally redundant family
member, CDK6. Yet, while CRISPR-mediated knockout of either CDK4 and CDK6 moder-
ately reduced cell fitness, only CDK4 loss synergized with TNKS inhibition to block cell cycle
progression, enhance apoptosis, and drive cell senescence. During the preparation of this man-
uscript, Menon and colleagues also identified an interaction between CDK4 and TNKS1/2
using a different small molecule TNKS inhibitor, MSC2504877[23]. Interestingly, in their
siRNA-based screening platform, they also identified CDK6 as a synthetic vulnerability with
TNKS inhibition. This apparent discrepancy in the role of CDK6 could be either due to the use
of different CRC cell lines in our screens, or differences between siRNA and CRISPR-based
approaches. Though, importantly, irrespective of reason underlying the difference, the data
presented herein raise the possibility that potent CDK4-selective inhibitors would most likely
enhance the response to TNKS/WNT inhibition, while potentially avoiding some of the on-
target toxicity of dual CDK4/6 inhibitors. Though there are no selective CDK4 inhibitors yet
commercially available, our data suggests they may prove effective in combination with WNT-
targeting molecules.
In addition to identifying synergies with TNKS inhibition, our screen also revealed some
possible CRC-selective dependencies. In particular, we identified a small set of genes (in partic-
ular VRK1, CSNK1A1, and PIK3R4) that were more dramatically depleted in colorectal cancer
cell lines, than a range of leukemia, liver and pancreatic cancer cell lines[22]. There is limited
in vivo data in the literature to assess whether these represent practical therapeutic targets,
though mouse studies have shown that hypomorphic VRK1 animals are viable[33], and abla-
tion of Csnk1a1 throughout the intestine does not disrupt normal homeostatic functions[34].
Further, while PIK3R4 deletion is embryonic lethal, it is not essential in all adult tissues[35].
Further work will be necessary to determine the requirement for these genes in normal and
transformed adult tissues.
TNKS inhibitors are often considered direct WNT targeting drugs, though TNKS has many
cellular targets in addition to AXIN1/2. In fact, Wang et al[27], recently reported that the syn-
ergy between TNKS and EGFR inhibition in lung cancer cells is due to reduction of YAP/
TAZ-mediated signaling via regulation of AMOT proteins[27]. Our data in colorectal cancer
cell lines, suggests that downstream induction of the WNT pathway by activating mutations in
CTNNB1 are sufficient to overcome the effects of TNKS blockade. Thus, at least in the CRC
cells examined here, WNT pathway inhibition is a critical component of TNKS-mediated
growth suppression. Further, while a number of the cell lines we assessed (e.g. MCF7, PC9)
have no known WNT pathway activating mutations, they have been shown to respond to
WNT-regulation [36–38]. However, given the breadth of TNKS targets, it is possible that
genetic or cell type-specific oncogenic programs create differential dependencies on TNKS, or
that the synergy observed between TNKS and CDK4 blockade is due to non-WNT dependent
signaling. In all, the data imply that TNKS enzymes act to support oncogenic transformation
through multiple independent mechanisms. Hence, while TNKS inhibitors may not always
provide significant anti-cancer responses as single agents[17, 20], they may prove effective as
part of specific treatment combinations, such as those described here and elsewhere[23].
Perhaps the most striking effect of combined TNKS/CDK4 inhibition was the robust induc-
tion of cell senescence. We observed this colon (DLD1 and SW480), breast (MCF7 and
MDA231), and lung cancer (A549, H23 and PC9) cells, while Lord and colleagues observed a
Tankyrase inhibition sensitizes cells to CDK4 blockade
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near identical effect in an independent CRC cell line, COLO320DM, together suggesting it is
not a cell-type specific phenomenon. The precise mechanism underlying the drug synergy that
leads to enhanced senescence remains intriguing, although multiple published examples that
WNT suppression blocks stemness programs and leads to profound chromatin changes that
precede the induction of senescent phenotypes[39–41]. This notion aligns with our observa-
tion that downstream WNT activation can bypass the effect of combined TNKS/CDK4 inhibi-
tion. The enhanced induction of senescence, as opposed to cell cycle arrest or apoptosis, may
have a beneficial impact in tumor therapy. Senescent cells secrete a range of inflammatory
cytokines–the senescence associated secretory phenotype (SASP)–that can activate immune
surveillance[42–45]. In some contexts, secreted factors from senescent cells recruit NK cells,
resulting in tumor cell elimination[46–48], while in others, the infiltration of monocytes and
granulocytes are the primary driver of senescent cell clearance[49]. In separate work, WNT
hyperactivation has been directly linked to immunotherapy failure[50–52]. It is important to
note that all of the work reported here has been performed in cancer cell lines in vitro, and it is
not known whether the senescence phenotypes induced by combined TNKS/CDK4 inhibition
will behave similarly in vivo. It will be important to determine whether combined suppression
of WNT and CDK4 could provide potent tumor responses in vivo and as an effective combina-
tion with current immune checkpoint inhibitors.
In all, our results demonstrate some of the practical applications of focused CRISPR screens
in identifying high-priority candidate liabilities. Follow up studies will demonstrate the practi-
cal applications in the clinic through co-clinical trials in matched patients and patient-derived
organoids, in which a rapid pipeline could help identify vulnerabilities and to predict potential
mechanisms of resistance to certain drug treatments.
Methods
Cell lines
Colon (DLD1, SW480, HCT116, HT29, LS174T, LoVo, T84 and SW620), breast (MDA-MB-
231 and MCF7), and lung (A549, H23 and PC9) cell lines were purchased from ATCC, tested
for mycoplasma and kept at low passage at all times (cells were discarded at passage >10).
Colon and breast cancer cell lines were maintained in DMEM containing 10% Fetal Bovine
Serum (FBS) and 1% Penicillin/Streptomycin (P/S). Lung cancer cell lines were grown in
RPMI supplemented with 10% FBS and 1% P/S. All the experiments were performed at pas-
sage >10 after reception from the ATCC.
Generation of Cas9-expressing clones
Cells were transduced with lentiviruses containing Cas9-P2a-Puro, selected for 72h in 2ug/ml
Puromycin, and plated following serial dilutions in 96 well plates (5 plates per cell line). 24h
later, wells containing a single cell were identified and picked when confluent, expanded and
tested with control gRNAs (EV) or gRNAs targeting pan-essential genes such as RPA3 or
CDK1[22]. Clones showing gRNA depletion kinetics similar to their parental counterparts
through fluorescent competition assays were selected for further experimentation.
CTNNB1 S45F base editing
We used puro-selected bulk FNLS-expressing DLD1 cells and further transduced them with a
LRT2B-CTNNB1-S45F gRNA. After selection in 10ug/ml Blasticidin, we isolated clones and
Sanger-sequenced the gDNA surrounding the mutation. S45F-confirmed clones were used for
subsequent experiments.
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Pooled negative-selection human kinome crRNA-based screen
A domain-focused kinome gRNA library[22] was used for assessing novel vulnerabilities and
TNKS-specific dependencies in CRC. This CRISPR pool was transduced into three DLD1
clones stably expressing SpCas9 using conditions that led predominantly to single lentiviral
integration per cell and ensuring a representation of at least 6,000 cells per gRNA. 48h after
transduction, cells were FACS-sorted for GFP expression. Half of the sorted cells (9 million
transduced cells; 3,000 cells per gRNA) were snap-frozen and kept for sequencing as original
library representation (Day 2), and the rest was allowed to recover for 7 days to ensure crRNA-
based genome editing. At Day 9 post-transduction, sorted cells were plated either in the pres-
ence of DMSO or 1ug/ml XAV939, replacing the medium every 2 days and splitting the plates
every 5 days while ensuring that at least 15 million cells were kept at each passage to maintain
sufficient library representation. After 14 population doublings (17 days) in the presence of
DMSO or XAV939, cells were snap-freeze collected as final timepoints (Day 17, PDL14).
Genomic DNA was extracted from Day2, Day17-DMSO and Day17-XAV939 using QIAGEN
DNA mini kit. 40 parallel PCRs were performed using 4ug of total gDNA as a template, pooled
using PCR purification kit (QIAGEN) and eluted in 85ul PCR-grade water. After template
repair, dA tailing, barcoding and pre-capture PCR as described[22], libraries were quality-
checked using Bioanalyzer. 8pM of each barcoded library[22] was analyzed on Illumina MiSeq
in pools of 4 samples per lane (MiSeq v2, 150x2 cycles). Two-by-two comparisons and adjusted
p-values of gRNA reads were calculated using DESeq R package.
Cumulative population doublings
5000 cells per well were seeded in 48-well plates and cultured for 20 days. Media was replaced
every 2 days and cells were split, counted and seeded at 5000 cells per well every 5 days. Cumu-
lative population doublings were calculated using the formula PDL = X0+3.322(logY-LogI)
were PDL stands for cumulative population doublings, X0 is the last number of doublings for
a given timepoint, Y is the final number of cells and I is the number of cells plated.
Drugs
XAV939, NVP636, G007-LK, Palbociclib, Gefitinib and Trametinib were purchased form Sell-
eckchem. All drugs were aliquoted at 20mM stocks and stored at -80C indefinitely. 1mM ali-
quots were prepared from these stocks and stored at -20C for 6–12 months. 1mM aliquots
were thawed once and aliquots in use were kept at 4C for a period <2 weeks (leftovers were
discarded if left unused after these periods of time). The working concentrations are indicated
in each Fig panel. Drugs in solution for cellular treatment were replenished every 48h by add-
ing fresh media.
Cloning
gRNAs were cloned into LRG or LRT2B lentiviral backbones using BsmBI restriction sites and
adapters as described elsewhere[22, 31]. All the primers and plasmids are listed in S5 Table.
Lentiviral transduction
293T cells were seeded at 90% confluence into 35mm dishes; 16h later, cells were transfected
using PEI as follows: 5ug plasmid, 2.5ug PAX2 packaging vector and 1.25ug VSVg envelope
vector were mixed into 150ul DMEM, vortexed 5 seconds and 30ul PEI were added and vor-
texed again; after 15min incubation at RT, transfection mix was added dropwise by swirling
the 293T cell plates. 24h later, the medium was replaced with collection medium, and viral
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supernatants were collected three times every 24h, pooled and preserved in 0.5ml aliquots at
-80C indefinitely. Target cells were seeded at 50,000 cells per well of a 12-well plate, and 24h
later the viral supernatant dilution containing 8ug/ml polybrene was added. 24h later the infec-
tion media was replaced with fresh media and cells were assayed or selected 48h post-
transduction.
Fluorescence-based competition assays
First, lentiviral supernatants were titrated for each cell line such that cells stably expressing
Cas9 would achieve a 30–60% TdTomato+ or GFP+ cells at Day3 post-transduction. This
timepoint was used for normalization of subsequent timepoints and these were represented as
a fraction of Day3 infection efficiency (= 1). 1/20th of the cells was plated in flat-bottom 96 well
plates and kept in culture by replacing the medium every 2 days. Cells were split every 5–7
days and fluorescence was assessed by flow cytometry using a BD Accuri C6 Plus or a Thermo-
Fisher Attune NxT flow cytometer, both of them with 96 well plate adapters. To do so, cells
were washed in 200ul of PBS, trypsinized in 50ul for 5min at 37C and resuspended in 200ul
complete medium using a multichannel pippete. 1/20th of the cell suspension was transferred
to a new plate and the rest was placed in a round-bottom 96 well plate compatible with the
autosampler device of the flow cytometer.
Senescence-associated beta-galactosidase staining
50,000 cells were seeded in 35mm dishes and pre-treated with each drug combo accordingly. 7
days later, cells were re-plated in 12 well plates at a density of 20.000 cells per well in the pres-
ence of drugs. 7 days later, cells were fixed and stained for beta-galactosidase activity using a
kit from Cell Signaling Technologies (Cat. No. #9860). Increased b-galactosidase activity at
pH6.0 detected by this approach reflects an increase in lysosomal β-D-galactosidase associated
with oncogene-induced and replicative senescence [53]. Micrographs were quantified using
Image J, and SABG-positive cells per field were normalized to the total number of cells per
field, and at least four fields (>300 cells) per condition from three independent experiments
were quantified. The drugs were replaced every 48h throughout the duration of the
experiment.
Cell cycle and EdU incorporation
EdU flow cytometry was performed using the Click-iT™ Plus EdU Alexa Fluor™ 647 Flow
Cytometry Assay Kit (Thermo Fisher, #C10634). After 15 days of treatment, cells were sub-
jected to EdU/PI staining following manufacturer’s instructions.
Western blot
200.000 cells were seeded in 35mm dishes and treated for the indicated times and conditions.
Upon collection, cells were washed in 1ml cold PBS and scrapped off into 150ul RIPA buffer,
incubated 15min on ice and centrifuged at 13.000rpm to collect protein lysates. 25ug per lane
were loaded; antibodies used and dilutions were anti-Axin1 (CST, #2087), anti-Tnks1/2 (Santa
Cruz, #sc-365897), anti-actin-HRP (Abcam, #ab49900), Anti-alpha-Tubulin (Millipore Sigma,
#CP06), anti-CyclinD1 (Santa Cruz, #sc-450), anti-CDK4 (Santa Cruz, #sc-56277), anti-EGFR
(Santa Cruz, #sc-373746) and anti-CDK6 (CST, #13331T).
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Colony-forming assays
Cells from a single-cell suspension were plated at a density of 1000 cells per well of a 12 well
plate in 500ul of complete medium containing no drugs. Indicated treatments were started
24h after plating and refreshed every 48h unless indicated until the end of the experiment.
After 15–25 days (when colonies were visible), cells were washed in PBS and fixed in a 4% PFA
solution in PBS for 1h at room temperature, then rinsed in PBS and stained overnight in an
orbital shaker using a 10% Giemsa solution in PBS. Then, plates were submerged in a distilled
water solution, rinsed 3 times in water and dried overnight. Digital pictures were acquired
with a BioRad Gel Doc device and pixel density was calculated using Adobe Photoshop. Exper-
iments were performed 3 times independently, and values were normalized to DMSO
controls.
Supporting information
S1 Fig. On target TNKS inhibition is not effective as monotherapy. a. Colony forming assay
quantification (top panel) and representative images (bottom panel) of cells grown in the indi-
cated inhibitor concentrations (n = 2). b. Western blot detection of Axin1 accumulation at dif-
ferent incubation timepoints using the indicated XAV doses.
(TIF)
S2 Fig. Domain-focused human kinome screen in colorectal cancer cells. a. Fluorescence
competition assays of DLD1 clones stably expressing pLenti-Cas9 and further transduced with
RPA3 gRNA or a control gRNA empty vector. b. Cell growth by cumulative population dou-
bling estimation in DLD1 cells treated as indicated with 1mM XAV or DMSO (n = 3). c. Dot
plots of the gRNA reads in two-by-two comparisons. Correlation coefficients (R2) across con-
ditions are shown. d. Volcano plot of Log10 adjusted p-values vs log2 fold-change in gRNA
representation in DMSO D17 vs post-sorting cells (D3, PS). In red, gRNAs significantly
depleted in DMSO. e. Normalized control (non-targeting) gRNA counts in DMSO (D17) vs
XAV (D17)-treated cells.
(TIF)
S3 Fig. Synergistic CDK4/6 and TNKS inhibition in multiple epithelial cell types. a. Left
panel, dot plot showing log10 Adj p values and log2 fold change of DMSO (D17) vs XAV
(D17) in DLD1 cells. Significantly represented gRNAs are highlighted in red. Right panel, rela-
tive gRNA abundance of human CDK protein members at D17 (DMSO) vs post-sorting (PS)
samples. b. Quantification of the colony forming assay shown in Fig 2F. DLD1 cells stably
expressing inducible shRNAs against TNKS were treated with the indicated drugs +/- dox. c.
Fluorescent competition assays in SW480 cells stably expressing shRNAs against TNKS1/2,
treated with Trametinib (left) or Palbociclib (right) +/- dox. The GFP positive cells represent
the proportion of shRNA-expressing fraction of each population, relative to D2 post-transduc-
tion. d. Colony forming assays (bottom panels) and quantification (top panels) of XAV and
Palbociclib combinations as indicated, for a panel of epithelial cells lines, including lung and
breast. N = 2–3 independent experiments, and p values represent Student’s t test.
(TIF)
S4 Fig. Canonical WNT signaling determines XAV-sensitization. a. Fluorescent competi-
tion assay in HCT116 clones stably expressing Cas9 and further transduced with the indicated
gRNAs, in the presence or absence of XAV. N = 3 clones, Student’s t test b. HCT116 cells
treated with the indicated doses of XAV and Palbociclib were seeded in colony-forming assays.
c. Quantification of cell proliferation inhibition in HCT116 cells treated with the indicated
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concentrations of Palbociclib or Gefitinib +/-XAV. d. shRNA-mediated knock-down of TNKS
does not influence cellular sensitivity to Palbociclib, Trametinib or Gefitinib in HCT116 cells.
e. Quantification of the experiment shown in (d). f. Trametinib sensitivity in DLD1 parental or
base-editing-generated S45F mutant isogenic DLD1 cell lines.
(TIF)
S1 Table. List of raw gRNA counts.
(CSV)
S2 Table. DESeq analysis of DMSO vs Post-sorting (PS) samples.
(CSV)
S3 Table. DESeq analysis of XAV vs Post-sorting (PS) samples.
(CSV)
S4 Table. DESeq analysis of DMSO vs XAV samples.
(CSV)
S5 Table. List of primers used in this study.
(CSV)
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